Prima Biomed News

Following our name change to become @Immutep last year, we will be shutting down this Twitter account soon. Stay up to date by following @Immutep!

[Prima Biomed News @Primabio]

Join us for a Key Opinion Leader call this week!

Immutep Ltd. will host a key opinion leader (KOL) call on novel immuno-oncology therapy (eftilagimod alpha) in the treatment of metastatic breast cancer and other settings.

Call will take place on... https://t.co/OqQFUjRYoB

[Prima Biomed News @Primabio]

James Dunn from nabtrade recently looked at Immutep Ltd. in his article 'Four ASX cancer stocks under the microscope', highlighting the potential for our lead product candidate, efti, and the opportunity stemming from our AIPAC phase II clinical trial:... https://t.co/Z9HNPgYZG2

[Prima Biomed News @Primabio]

Immutep Ltd. has been granted another US patent for efti.

This new patent provides intellectual property protection for Immutep’s method of treating cancer by the administration of a chemotherapy agent, and a plurality of doses of efti.... https://t.co/NzZ0nyUfAS

[Prima Biomed News @Primabio]

Join us for a global webcast to discuss Immutep Ltd.'s recent preclinical results relating to IMP761 in #autoimmunedisease on:

Tuesday, March 26, 2019, 7:45 am Australian Eastern Daylight Time,
or
Monday, March 25, 2019, 4:45 pm US Eastern Daylight... https://t.co/EQHyy9sCST

[Prima Biomed News @Primabio]

Marc Voigt spoke with Finance News Network
about Immutep Ltd.'s recent progress and exciting news flow ahead.

Even with a busy week of data behind us, from TACTI-mel and IMP761, Immutep still has a great deal of clinical data that it will report... https://t.co/K4G7tGyiEB

[Prima Biomed News @Primabio]

Late last week, Immutep Ltd. received a A$872,351 cash rebate from the Australian Federal Government’s R&D tax incentive program.

The rebate is for its eligible R&D activities conducted in the 2018 fiscal year and is mainly related to the Company’s... https://t.co/quZRxEMUhh

[Prima Biomed News @Primabio]

Immutep Ltd. today announced positive results from its preclinical study of IMP761, a novel LAG3 agonist antibody being developed for the treatment of #AutoimmuneDiseases.

This new study showed that IMP761 decreases inflammatory T cell infiltration... https://t.co/0CHUlWKGE6

[Prima Biomed News @Primabio]

Immutep Ltd. today announced positive, more mature data from its ongoing TACTI-mel phase I clinical study of the Company’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”). The data will be presented at the World Immunotherapy Congress... https://t.co/VXYMUL5MfU

[Prima Biomed News @Primabio]

Immutep Ltd. has published its half year report for the period ended 31 December 2018, on Immutep Ltd and its subsidiaries. Click the link below to the Half Year Report https://t.co/IhmPfgI6DY

[Prima Biomed News @Primabio]

Immutep Ltd. has published its half year report for the period ended 31 December 2018, on Immutep Ltd and its subsidiaries.

Click the link below to the Half Year Report https://t.co/IhmPfgI6DY

[Prima Biomed News @Primabio]

Immutep Ltd. will be presenting updated clinical data from the Phase I TACTI-mel trial in metastatic melanoma for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) at World Immunotherapy Congress USA 2019 being held from 3-5 March 2019.... https://t.co/VO1VAkEFse

[Prima Biomed News @Primabio]

Our new collaboration with CYTLIMIC has been covered by online publication Stockhead.

"Cancer biotech Immutep’s flagship drug is to be used in conjunction with a cancer peptide vaccine discovered by artificial intelligence in new Japanese clinical... https://t.co/dh0bvpt166

[Prima Biomed News @Primabio]

Immutep Ltd.'s recent news, including two new EU patents and further TACTI-mel data, has been highlighted in online news publication, Small Caps. https://t.co/83ULoatV8N

[Prima Biomed News @Primabio]

Immutep Ltd. CEO Marc Voigt spoke with FNN about the Company's recent progress, its new partnerships and what's coming up next in terms of meaningful clinical work.
#Immunotherapy https://t.co/XdPc310c5Y

[Prima Biomed News @Primabio]

Immutep Ltd.'s partner CYTLIMIC recently presented the results of its YNP001 study at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting.

The YNP001 study is a First-in-Human study of the cancer peptide vaccine... https://t.co/arlkDWncQQ

[Prima Biomed News @Primabio]

Immutep Ltd. today announced new positive interim data from its ongoing TACTI-mel Phase I clinical trial, presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., U.S.

Dr. Frédéric Triebel, Immutep’s... https://t.co/y1GOPJZuki

[Prima Biomed News @Primabio]

Immutep Ltd. CEO Marc Voigt recently spoke with Your Money's Ingrid Willinge about the Company's growing trial and partnership momentum. https://t.co/Q2LFNfZiaw

[Prima Biomed News @Primabio]

Immutep Ltd. today provided an operational update on the Company’s ongoing clinical and preclinical development of eftilagimod alpha (“efti” or “IMP321”) and IMP761, respectively, as well as the Company’s partnered clinical programs.

Highlights... https://t.co/2TejbWa0fW

[Prima Biomed News @Primabio]

This Washington Post video (via the article) includes a good explanation of how Nobel Laureates and cancer researchers James P. Allison and Tasuku Honjo revolutionised cancer treatment by determining how to disengage the “brakes” that prevent the... https://t.co/6GA0xXrLI2

[Prima Biomed News @Primabio]

Congratulations to Dr Allison and Dr Honjo, two of the world’s best cancer #immunotherapy... https://t.co/LP9ehnSw07